Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the effects of 8 weeks’ administration of exenatide (EXE) once weekly on gastric emptying of solids and liquids (using the “gold standard” technique, scintigraphy), glucose absorption and postprandial glycaemia in healthy people. Material and methods: A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m 2 ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ± 1.0 kg/m 2 ) for 8 weeks. Gastric emptying, nausea (visual analogue scale), and plasma glucose, insulin, C‐peptide and glucagon were measured for 120 min after a solid/liquid meal, comprising 100 g ground beef (radiolabelled with 20 MBq 99m Tc‐sulphur colloid) and 150 mL 10% glucose (radiolabelled with 7 MBq 67 Ga‐EDTA), and containing 5 g 3‐O‐methyl‐glucose (3‐OMG) as a marker of glucose absorption, at baseline and after 8 weeks’ treatment. Results: The study treatments were well tolerated. Scores for nausea were consistently low, with no difference between the EXE once weekly and PBO groups. EXE once weekly slowed gastric emptying of solids (area under the curve [AUC] 0–120min : P < 0.05) and liquids (AUC 0–120min : P = 0.01) substantially, and attenuated glucose absorption (3‐OMG incremental AUC [iAUC] 0–30min : P = 0.001) and the postprandial rise in plasma glucose (iAUC 0–30min : P = 0.008). Plasma glucagon at 2 h was reduced by EXE once weekly ( P = 0.001). The magnitude of the reduction in plasma glucose at t = 30 min from baseline to 8 weeks with EXE once weekly was related inversely to the 50% emptying time of the glucose drink ( r = −0.55, P = 0.03). Conclusions: In healthy participants, 8 weeks’ administration of the “long‐acting” glucagon‐like peptide‐1 receptor agonist EXE, slowed gastric emptying of solids and liquids substantially, with consequent reductions in glucose absorption and postprandial glycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 12×
“Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are used widely, and increasingly, in the management of type 2 diabetes(1,2) and, on the basis of their plasma half-life, may be classified as “short-” (eg, exenatide [EXE] twice daily, lixisenatide) or “long-” (eg, EXE once weekly, liraglutide, dulaglutide, sema…”
BackgroundResultInfluentialNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“Comparative studies of EXE once weekly with EXE twice daily in type 2 diabetes indicate that EXE once weekly is associated with greater reductions in fasting/preprandial glucose, while EXE twice daily leads to greater reductions in postprandial glucose.(1,29) This is also the case when liraglutide is compared to lixis…”
BackgroundNauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469 · cited 1×
“ponent), consistent with previous studies establishing gastric emptying as a major determinant of early postprandial glycaemia.(11,12) This is despite the predictably modest glycaemic response in healthy participants.”
ResultSelf-citationSchvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M., & Berne, C. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70080-5 · Cited by 416
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 2×
“hence, have a dominant postprandial effect, while long-acting GLP-1RAs may have minimal or no effect on gastric emptying with sustained administration as a result of tachyphylaxis, so that their glucose-lowering is preferentially preprandial, reflecting stimulation of insulin and suppression of glucagon.(21,24) This c…”
BackgroundMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Gastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273 · cited 2×
“Their current use is essentially empirical, rather than “personalized” as is increasingly recommended.(1,2) A number of long-acting GLP-1RAs have been shown to reduce cardiovascular risk.”
BackgroundSelf-citation
Cited by
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Self-citationvan Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87
“exenatide once weekly [QW], liraglutide, dulaglutide, semaglutide [subcutaneous and oral] and tirzepatide [a dual GIP/GLP-1 receptor agonist]) on gastric emptying have, for the main part, been evaluated with the suboptimal paracetamol test [17, 39–43], rather than a more accurate technique [44].”
BackgroundMethodInfluentialSelf-citationQuast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-0720 · Cited by 64
Milder, D. A., Milder, T. Y., Liang, S. S., & Kam, P. C. A. (2024) · Anaesthesia · doi:10.1111/anae.16306 · Cited by 62
“Scintigraphy, the gold standard for measuring gastric emptying, has shown delayed gastric emptying in patients with diabetes and patients with obesity on exenatide (both short-and long-acting) [39 – 41], liraglutide [42] and semaglutide [43].”
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Self-citationZhang, Z., Zhang, Q., Tan, Y., Chen, Y., Zhou, X., Liu, S., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149328 · Cited by 46
“05) (39) HV 8week Exenatide 2mg qw Placebo 35 60.”
BackgroundCamilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Glucagon‐like peptide‐1 receptor agonists and the appropriate measurement of gastric emptying
Horowitz, M., Rayner, C. K., Marathe, C. S., Wu, T., & Jones, K. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14166 · Cited by 32
“For example, in health, exenatide once-weekly slows emptying of solids and liquids after 8 weeks’ administration; moreover, the reduction in postprandial glucose is related to the magnitude of this slowing.(11) An effect of exenatide once-weekly on gastric emptying was ‘missed’ using the paracetamol test.”
BackgroundSelf-citationRayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
“tribute to the lower incidence of GI AEs with long-acting GLP-1 RAs; however, it has recently been demonstrated that exenatide once weekly slows gastric emptying significantly even at steady-state concentrations.(38) Moreover, the suppression of energy intake by lixisenatide is”
BackgroundSelf-citationJalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2019 · Cited by 18
Self-citation
Metadata
- Authors
- Jones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C. H., Stevens, J. E., Lange, K., Rayner, C. K., & Horowitz, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-01-28
- Volume
- 22
- Issue
- 5
- Pages
- 788-797
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2998516536
- Cited by
- 76
- References
- 19
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.